ANI Pharma (ANIP) Tops Q1 EPS by 60c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ANIP Hot Sheet
Join SI Premium – FREE
ANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $2.05, $0.60 better than the analyst estimate of $1.45. Revenue for the quarter came in at $237.5 million versus the consensus estimate of $213.42 million.
GUIDANCE:
ANI Pharma sees FY2026 EPS of $9.19-$9.69, versus the consensus of $9.07. ANI Pharma sees FY2026 revenue of $1.08-1.14 billion, versus the consensus of $1.09 billion.
For earnings history and earnings-related data on ANI Pharma (ANIP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eaton (ETN) spreaders of November 6 weekly 397.50, November 6 weekly 440, November 420 and November 470 calls as share price down 7%
- Power Solutions (PSIX) call put ratio 1 call to 10.8 puts with a focus on 2500 contracts of November 45 puts
- Visteon (VC) Misses Q3 EPS by 214c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
